BridgeBio price target raised to $50 from $44 at JPMorgan

JPMorgan raised the firm’s price target on BridgeBio (BBIO) to $50 from $44 and keeps an Overweight rating on the shares. The firm surveyed 30 U.S. cardiologists to better understand the uptake of recently approved transthyretin amyloid cardiomyopathy products, including BridgeBio’s Attruby. The firm is “very encouraged” that 37% of surveyed physicians gave at least slight edge to Attruby in overall clinical profile relative to Pfizer’s Vyndaqel and Vyndamax, given the early stage of the launch. The survey results suggest “very strong” Attruby uptake in both newly diagnosed and Vyndaqel/Vyndamax progressor populations, the analyst tells investors in a research note.